β-tubulin Ⅲ在结肠腺癌组织中的表达及其临床意义

doi:10.13481/j.1671-587x.20170421

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (04): 770-775.doi: 10.13481/j.1671-587x.20170421

β-tubulin Ⅲ在结肠腺癌组织中的表达及其临床意义

石俊忠¹, 庄建彬¹, 张传山², 刘贤明³, 孔大陆⁴

1. 天津市第三中心医院普外科, 天津 300170;
2 天津市第三中心医院病理科, 天津 300170;
3. 天津医科大学肿瘤医院肿瘤内科, 天津 300060;
4. 天津医科大学肿瘤医院结直肠肿瘤科, 天津 300060

收稿日期:2017-02-04 出版日期:2017-07-28 发布日期:2017-08-01
通讯作者: 石俊忠,副主任医师,副教授(Tel:022-84112181,E-mail:871655161@qq.com) E-mail:871655161@qq.com
作者简介:石俊忠(1963-),男,天津市人,副主任医师,副教授,主要从事普通外科和胃肠肿瘤外科临床方面的研究。
基金资助:
天津市卫计委重点攻关项目资助课题（15KG116）

Expression of β-tubulin Ⅲ in colon adenocarcinoma tissue and its clinical significance

SHI Junzhong¹, ZHUANG Jianbin¹, ZHANG Chuanshan², LIU Xianming³, KONG Dalu⁴

1. Department of General Surgery, Tianjin Third Central Hospital, Tianjin 300170, China;
2. Department of Pathology, Tianjin Third Central Hospital, Tianjin 300170, China;
3. Department of Oncology Cancer Hospital, Tianjin Medical University, Tianjin 300060, China;
4. Department of Colorectum Oncology, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China

Received:2017-02-04 Online:2017-07-28 Published:2017-08-01

摘要/Abstract

摘要： 目的：检测结肠腺癌患者癌组织中β-tubulin Ⅲ的表达，探讨其临床意义。方法：收集结肠腺癌组织标本111例，根据β-tubulin Ⅲ的阳性细胞分布部位分为浸润前沿组（n=72例）和非浸润前沿组（n=39例），采用免疫组织化学法检测结肠腺癌患者癌组织中β-tubulin Ⅲ的阳性表达率，分析β-tubulin Ⅲ的表达与患者性别、年龄、肿瘤分化、临床分期、淋巴结转移、复发和死亡等临床病理特征之间的关系。结果：不同性别、淋巴结转移、临床分期、死亡和复发结肠腺癌患者间β-tubulin Ⅲ的阳性表达率比较差异无统计学意义（P>0.05）。浸润前沿组和非浸润前沿组患者癌组织中β-tubulin Ⅲ阳性表达率比较差异有统计学意义（χ²=8.76，P=0.01）。低中分化病例多见于浸润前沿组，而高分化病例多见于非浸润前沿组（χ²=6.88，P=0.03）。不同分化程度癌组织中β-tubulin Ⅲ的阳性表达率比较差异有统计学意义（χ²=5.74，P=0.04）。非前沿组中有无淋巴结转移的患者癌组织中β-tubulin Ⅲ阳性表达率比较差异有统计学意义（χ²=6.02，P=0.05）。免疫组织化学法染色，β-tubulin Ⅲ阳性表达细胞胞质呈黄色颗粒；与低分化组比较，高分化癌组织中β-tubulin Ⅲ阳性表达细胞明显增多。结论：结肠腺癌组织中β-tubulin Ⅲ表达与肿瘤的分化程度有关，高分化结肠腺癌组织多见于非浸润前沿组。非浸润前沿组患者β-tubulin Ⅲ表达与淋巴结转移有关。

关键词: 腺癌, β-tubulin Ⅲ, 结肠肿瘤, 免疫组织化学

Abstract: Objective: To detect the expression and clinical significance of β-tubulin Ⅲ in cancer tissue of the patients with colon adenocarcinoma,and to explore its clinical significance.Methods: A total of 111 colon adenocarcinoma tissue samples were obtained. According to the location of β-tubulin Ⅲ positive cells, all patients were divided into front group (n=72) and non-front group (n=39). The positive expression rate of β-tubulin Ⅲ in the patients with colon adenocarcinoma was detected with immunohistochemistry. The correlations among the expression of β-tubulin Ⅲ and gender,age,tumor differentiation, clinical stage, lymph node metastasis, recurrence and death were analyzed.Results: The expression levels of β-tubulin Ⅲ had no significant differences between the patients with different gerder,age,lymph node metastasis,clinical stages,death and recurrence.The positive expression rates of β-tubulin in cancer tissue of the patients had significant difference between front and non-front groups (χ²=8.76, P=0.01). Lowly-to-moderately differentiated tissue was more common in front group, and highly-differentiated tissue was more common in non-front group(χ²=6.88, P=0.03). There were significant differences in the expression levels of β-tubulin Ⅲ between cancer tissues with different differentiation degrees (χ²=5.74, P=0.04). In non-front group, lymph node metastasis was closely correlated with the expression of β-tubulin Ⅲ (χ²=6.02,P=0.05). The resultsof immunohistochemical staining showed that the β-tubulin Ⅲ positive-expressing cells were colored brown-yellow. The number of cells with positive β-tubulin Ⅲ expression was significantly increased in highly differentiated tissue compared with low-differentiated tissue.Conclusion: The expression of β-tubulin Ⅲ is closely related to tumor differentiation in colon adenocarcinoma tissue. The highly differentiated colon adenocarcinoma tissue is more common in non-front group in which the expression of β-tubulin Ⅲ is related to lymph node metastasis.

Key words: colonic neoplasms, adenocarcinoma, Β-tubulin Ⅲ, immunohistochemistry

中图分类号:

R735.35

石俊忠, 庄建彬, 张传山, 刘贤明, 孔大陆. β-tubulin Ⅲ在结肠腺癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2017, 43(04): 770-775.

SHI Junzhong, ZHUANG Jianbin, ZHANG Chuanshan, LIU Xianming, KONG Dalu. Expression of β-tubulin Ⅲ in colon adenocarcinoma tissue and its clinical significance[J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 770-775.

参考文献

[1] Zhu J, Tan Z, Hollis-Hansen K, et al. Epidemiological trends in colorectal cancer in China:An ecological study[J]. Dig Dis Sci, 2017,62(1):235-243.
[2] Verdier-Pinard P, Wang F, Martello L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry[J]. Biochemistry, 2003, 42(18):5349-5357.
[3] 权继传,解亦斌,田艳涛. 国际抗癌联盟胃癌TNM分期系统第七版解读[J]. 中华诊断学电子杂志,2014,2(1):59-61.
[4] Fife CM, McCarroll JA, Kavallaris M. Movers and shakers:cell cytoskeleton in cancer metastasis[J]. Br J Pharmacol, 2014, 171(24):5507-5523.
[5] Klute K, Nackos E, Tasaki S, et al. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy[J]. Onco Targets Ther, 2014, 7:2227-2236.
[6] Portyanko A, Kovalev P, Gorgun J, et al. β Ⅲ-tubulin at the invasive margin of colorectal cancer:possible link to invasion[J]. Virchows Arch, 2009, 454(5):541.
[7] 曹友红,马平,王福根,等. β-tubulin Ⅲ在胃癌中的表达及临床意义[J]. 新医学,2014(7):444-447.
[8] Tsourlakis MC, Weigand P, Grupp K, et al. β Ⅲ-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion[J]. Am J Pathol, 2014, 184(3):609-617.
[9] Koh Y, Kim TM, Jeon YK, et al. Class Ⅲ-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma[J]. Ann Oncol, 2009, 20(8):1414-1419.
[10] Lebok P, Öztürk M, Heilenk tter U, et al. High levels of class Ⅲ β-tubulin expression are associated with aggressive tumor features in breast cancer[J]. Oncol Lett, 2016, 11(3):1987-1994.
[11] Du J, Li B, Fang Y, et al. Overexpression of class Ⅲ β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage Ⅲ ovarian epithelial cancer[J]. BMC Cancer, 2015, 15(1):536-547.
[12] Melling N, Tsaklakidis AM, Simon R, et al. β Ⅲ-tubulin overexpression is linked to left-sided tumor localization and nuclear β-catenin expression in colorectal cancer[J]. Cancer Treat Commun, 2015, 6(4):96-102.
[13] 杨清海, 陈惠玲, 曾德华,等. 非黏液型肺腺癌中β-Tubulin-Ⅲ作为早期浸润灶标志物的应用[J]. 临床与实验病理学杂志,2016,32(7):753-756.
[14] Izutsu N, Maesawa C, Shibazaki M, et al. Epigenetic modification is involved in aberrant expression of class Ⅲ beta-tubulin, TUBB3, in ovarian cancer cells[J]. Int J Oncol, 2008, 32(6):1227-1235.
[15] Zou ZQ, Du YY, Sui G, et al. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.[J]. Asian Pac J Cancer Prev, 2015, 16(8):3189-3194.
[16] 杨立伟,韩青松,栾艳超,等. 食管鳞癌患者ERCC1、TYMS、TUBB3的表达特征及其与化疗效果的相关性分析[J]. 基因组学与应用生物学, 2016(11):2941-2945.
[17] Lu M, Gao J, Wang X, et al. Expressions of thymidylate synthase, thymidine phosphorylase, class Ⅲ β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin[J]. Chin J Cancer Res, 2011, 23(4):288-294.
[18] Aldonza MBD, Hong JY, Alinsug MV, et al. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation[J]. Oncotarget, 2016, 7(23):34395-34419.
[19] 钟科. TUBB3和TOP2A与晚期乳腺癌患者临床病理特征及与紫杉类联合蒽环类药物治疗疗效的关系[J]. 第三军医大学学报, 2016, 38(14):1659-1663.
[20] Ming X, Yi T, Chen WW, et al. Tubb3 regulation by the Erk and Akt signaling pathways:a mechanism involved in the effect of arginine ADP-ribosyltransferase 1(Art1) on apoptosis of colon carcinoma CT26 cells[J]. Tumor Biol, 2016, 37(2):2353-2363.
[21] Yang Z, Liu Y, Shi C, et al. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways[J]. Oncol Rep, 2017, 37(2):1011-1019.

β-tubulin Ⅲ在结肠腺癌组织中的表达及其临床意义

Expression of β-tubulin Ⅲ in colon adenocarcinoma tissue and its clinical significance

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	王廷刚, 薛峰, 李宇, 牛兆健, 王野. miR-26a靶向HMGA1基因对结肠癌细胞生长、侵袭和迁移的影响[J]. 吉林大学学报(医学版), 2018, 44(06): 1205-1211.
[2]	李红霞, 宫海叶, 曾萧, 张素素, 刘伯锋. TGF-β1和PLGF在不同类型妊娠滋养细胞疾病患者病变组织中的表达及其意义[J]. 吉林大学学报(医学版), 2018, 44(05): 1041-1046.
[3]	赵振理, 畅继武, 孙光, 胡少华. AAX14401蛋白在人膀胱癌组织中的表达及其意义[J]. 吉林大学学报(医学版), 2018, 44(05): 1052-1055.
[4]	王天月, 崔晓燕, 吴骁, 王丹. 磷酸化胞外信号调节激酶在小鼠海马发育过程中的表达及其意义[J]. 吉林大学学报(医学版), 2018, 44(05): 979-982.
[5]	阎慧, 娄石磊, 苗永迪, 岂蕊, 郭子硕, 邱悦, 孙聪. 大鼠结肠原代成纤维细胞的分离、培养和鉴定[J]. 吉林大学学报(医学版), 2018, 44(04): 849-852.
[6]	张啸环, 段明华, 闫玉礼, 潘新, 李海清, 周长龙, 赵天倚. 人羊膜成纤维细胞的分离和鉴定[J]. 吉林大学学报(医学版), 2018, 44(04): 845-848.
[7]	魏佳, 王瑶琪, 孙旭, 逄仁柱, 杨帅, 石亮, 李勇, 孟宪瑛. 甲状腺癌相关基因及其在临床诊断中应用的研究进展[J]. 吉林大学学报(医学版), 2018, 44(04): 880-885.
[8]	周刘祥, 林琳, 胡鑫敏, 王晓春. 内分泌腺性血管内皮生长因子对结肠癌LoVo细胞增殖和迁移的促进作用[J]. 吉林大学学报(医学版), 2018, 44(03): 516-520.
[9]	包幸福, 倪宇昕, 李莹, 郭小凯, 王玉琢, 方蛟, 胡敏. Wnt5a在小鼠牙骨质发育中的表达特点及其对成牙骨质细胞分化的影响[J]. 吉林大学学报(医学版), 2018, 44(03): 461-465.
[10]	范励雯, 付彤, 古林, 吴迪, 贾泓瑶, 宋东. 副乳腺癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 412-415.
[11]	杨易, 包康达, 周彦兵, 袁超, 李勇, 刘晓明, 徐金瑞. Wnt5a对人肺腺癌A549细胞凋亡的调控作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(02): 229-234.
[12]	马啸天, 岳小欣, 荣守华, 张玉超, 田远, 石瑛, 李君芳, 贾莉婷. miR-200c对三阴性乳腺癌上皮间质转化的抑制作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(01): 106-110.
[13]	林晓萌, 丁琪琼, 陈鹊汀, 张磊, 郝鑫, 李中. 灵芝酸A对人炎性乳腺癌细胞体外增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 116-120.
[14]	马晓周, 刘麒麟, 尹唯凰, 王越, 于阳, 杨刚, 于子莹. CC趋化因子受体6在人唾液腺腺样囊性癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(01): 147-150.
[15]	王玥, 刘畅, 朴仙姬, 张冬云, 孟令旗, 王浩, 王加茹, 罗英花, 孙虎男, 金成浩. 四溴苯三唑对人结肠癌SW480细胞凋亡的诱导作用及其机制[J]. 吉林大学学报(医学版), 2017, 43(06): 1148-1154.